WO2012053768A3 - Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient - Google Patents

Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient Download PDF

Info

Publication number
WO2012053768A3
WO2012053768A3 PCT/KR2011/007589 KR2011007589W WO2012053768A3 WO 2012053768 A3 WO2012053768 A3 WO 2012053768A3 KR 2011007589 W KR2011007589 W KR 2011007589W WO 2012053768 A3 WO2012053768 A3 WO 2012053768A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
same
compound
pharmaceutical composition
active ingredient
Prior art date
Application number
PCT/KR2011/007589
Other languages
French (fr)
Other versions
WO2012053768A2 (en
Inventor
Mi-Sun Won
Hwan-Mook Kim
Kyeong Lee
Song-Kyu Park
Ki-Ho Lee
Chang-Woo Lee
Jung-Joon Lee
Kyung-Sook Chung
Bo-Kyung Kim
Ying-Lan Jin
Original Assignee
Korea Research Institute Of Bioscience And Biotechnology
Dongguk University Industry-Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute Of Bioscience And Biotechnology, Dongguk University Industry-Academic Cooperation Foundation filed Critical Korea Research Institute Of Bioscience And Biotechnology
Publication of WO2012053768A2 publication Critical patent/WO2012053768A2/en
Publication of WO2012053768A3 publication Critical patent/WO2012053768A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Abstract

Disclosed are a compound inhibitory of HIF-1 activity, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound has anticancer activity which is attributable to its inhibitory activity against HIF-1, but not to non-selective cellular toxicity. Thus, having inhibitory activity against HIF-1, the compound or a pharmaceutically acceptable salt thereof can be used as an ingredient in an anticancer agent for various cancers including large intestine cancer, hepatic cancer, stomach cancer and breast cancer. Further, the compound or a pharmaceutically acceptable salt thereof is applicable to the treatment of diabetic retinopathy or arthritis which is aggravated upon the activation of VEGFA by HIF-1.
PCT/KR2011/007589 2010-10-20 2011-10-12 Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient WO2012053768A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100102662A KR101501576B1 (en) 2010-10-20 2010-10-20 Aryloxyphenoxyacetyl-based compound having HIF-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
KR10-2010-0102662 2010-10-20

Publications (2)

Publication Number Publication Date
WO2012053768A2 WO2012053768A2 (en) 2012-04-26
WO2012053768A3 true WO2012053768A3 (en) 2012-06-21

Family

ID=45975693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007589 WO2012053768A2 (en) 2010-10-20 2011-10-12 Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient

Country Status (2)

Country Link
KR (1) KR101501576B1 (en)
WO (1) WO2012053768A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107226785A (en) * 2017-06-11 2017-10-03 长春工业大学 Adamantane styrenic derivatives and its preparation method and application

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101599259B1 (en) * 2013-12-04 2016-03-03 일동제약주식회사 HIF-1 HIF-1inhibitor for treating the desease concerning angiogenesis
CN111105807B (en) * 2014-01-15 2023-09-15 三星电子株式会社 Weighting function determining apparatus and method for quantizing linear predictive coding coefficient
WO2015111967A1 (en) * 2014-01-23 2015-07-30 동국대학교 산학협력단 Phenoxyacryl derivative and use thereof
CN105085287A (en) * 2014-05-12 2015-11-25 上海医药工业研究院 Preparation method of 3'-amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
CN105085276A (en) * 2014-05-12 2015-11-25 上海医药工业研究院 Eltrombopag intermediate and preparation method therefor and application thereof
KR102274238B1 (en) 2020-01-23 2021-07-09 동국대학교 산학협력단 Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition and kit for inhibiting the growth of cancer containing the same as an active ingredient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008004798A1 (en) * 2006-07-04 2008-01-10 Korea Research Institute Of Bioscience And Biotechnology Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008004798A1 (en) * 2006-07-04 2008-01-10 Korea Research Institute Of Bioscience And Biotechnology Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAE YOON CHUNG ET AL.: "Pharmacophore-based 3D-QSAR of HIF-1 Inhibitors", AR CH. PHARM. RES.., vol. 32, no. 3, 2009, pages 317 - 323, XP055146772, DOI: doi:10.1007/s12272-009-1301-3 *
KYEONG LEE ET AL.: "LW6, a novel HIF-1 inhibitor, promotes proteasomal degra dation of HIF-l avia upregulation of VHL in a colon cancer cell line", BIOCHE MICAL PHARMACOLOGY, vol. 80, no. 7, 23 June 2010 (2010-06-23), pages 982 - 989 *
SHANTHAVEERAPPA K. BOOVANAHALLI ET AL.: "Synthesis of (aryloxyacetylamino)-i sonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF) -1 alpha inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 22, 2007, pages 5376 - 5379 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107226785A (en) * 2017-06-11 2017-10-03 长春工业大学 Adamantane styrenic derivatives and its preparation method and application

Also Published As

Publication number Publication date
WO2012053768A2 (en) 2012-04-26
KR20120041071A (en) 2012-04-30
KR101501576B1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
WO2012053768A3 (en) Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
WO2008004798A8 (en) Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
RU2573392C3 (en) COMPOSITION CONTAINING TETRACYCLIC COMPOUNDS
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
BR112012027743A2 (en) cyclopropyl dicarboxamides and analogs exhibiting anticancer and antiproliferative activities
MX2012015279A (en) Tetrahydrocarboline derivative.
WO2016080810A3 (en) Biguanide compound and use thereof
RU2018135973A (en) PHARMACEUTICAL COMBINATION CONTAINING METROFORMIN AND DYHYDROQUERCENINE, AND ITS APPLICATION FOR TREATING CANCER
WO2014101295A3 (en) Isoxazole derivative that inhibits activity of janus kinases (jaks)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
WO2011159100A3 (en) Anti-cancer pharmaceutical composition
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
MY163762A (en) Therapeutic agent for chronic renal failure
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012053787A3 (en) Aryloxy phenoxy acrylic compound having hif-1 inhibition activity, method for preparing same, and pharmaceutical composition containing same as an active ingredient
MY158693A (en) Formulation comprising phenylaminopyrimidine derivative as active agent
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
WO2012143624A3 (en) Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
MY173812A (en) 2-pyridone compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11834568

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11834568

Country of ref document: EP

Kind code of ref document: A2